drugset / Trial / NCT07297238

Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.

NCT07297238 ↗

Completed 20 enrolled Jinling Hospital, China
RandomizedParallel-groupSingle-blindTreatment

Summary

Eligible patients were randomized into two groups: the GLP-1 group and the control group. The control group received a placebo along with standard care, without any additional GLP-1-based intervention. The GLP-1 group, in addition to standard care, received a subcutaneous injection of a GLP-1 analog (semaglutide injection) strictly according to the drug manufacturer's instructions. The initial dose of semaglutide was 0.25 mg once weekly. Treatment was continued over a 28-days period. Primary and secondary outcomes will be collected.

Timeline

Start
2026-01-24
Primary completion
2026-05-27
Completion
2026-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject GLP-1 Receptor Agonists Unknown 0.25 mg —